INVESTORS

OVERVIEW

Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Clinical laboratory tests save costs and lives by enabling early detection and prevention of disease.

Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology.

At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.

ColoAlert, Lead Product Highlights

Significant Impact

Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.1

Revenue Generating

ColoAlert has received CE accreditation and is approved for sale in Europe. European sales provide near-term revenue potential, while we prepare our entry into the US market.

Blue Sky Potential

We plan on starting the FDA process shortly after our public listing.  Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52 million tests per year. (a)
Ease of Use
Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.3,(b)

Attractive Valuation Potential

Our closest peer, Exact Sciences (NASDAQ: EXAS) – ColoGuard product is only sold in the US – has a market cap of approximately 16.5 billion USD. 

Experienced Management

Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world. 

1 Colorectal cancer is the second leading cause of cancer death in the US – Cancer.org

2 Sensitivity is the ability of a test to correctly identify those with the disease (true positive rate), whereas test specificity is the ability of the test to correctly identify those without the disease (true negative rate).

3 As defined in ColoAlert instructions for use.

(a) See more information here

(b) See more information here

MAINZ BIOMED AIMS TO BECOME A LEADER IN THE MULTI-BILLION-DOLLAR COLORECTAL CANCER DIAGNOSTICS MARKET

If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.